HA TECH
At the Forefront of Developing Innovative Biotechnology

Diagnostics deserves all the attention as drugs and vaccines when it comes to global health. The Covid-19 pandemic has cast the spotlight on the critical importance of early and rapid diagnosis for clinical management of illness and containing outbreaks. Nobody understands this better than HA TECH. An Australian-based biotechnology company, HA TECH develops and delivers innovative diagnostic and pharmaceuticals products focusing on the diagnosis of serious infectious diseases. These include respiratory, including COVID-19, sexually transmitted infection (STI), Gastroenteritis, and mosquito-borne diseases that affect hundreds of millions of people worldwide and are among the most urgent global health challenges. As members of the global healthcare community, HA TECH focuses on reducing the burden of disease with innovative products and the development of novel technologies. The company aims to be inclusive and make diagnostic products that are accessible, requiring basic laboratory equipment rather than restricting users to specific brand equipment.

“There is no alternative to having an accurate diagnostic result for doctors to be able to treat patients. HA Tech believes in providing world class diagnostic products with an affordable price tag that is accessible for everyone. Every country (Developing or Developed) should be able to use our world class Australian Made products,” says Abdullah Mahmud, Executive Chairman of HA TECH.

Currently, HA TECH’s clients are facing challenges with sourcing reliable and accurate diagnostic kits that are both affordable and able to detect all emerging variants of Covid-19. The HA TECH SARS-CoV-2 RT PCR Multiplex kit (NAT-01) beats any other commercial kits in the market with the best sensitivity and performance possible and the shortest run time to provide the most efficient testing solution to COVID-19. One of the major features of the kit is the time efficiency with 45 minutes total PCR run time.

With existing equipment and resources, labs can increase their testing capacity by 100 to 200 percent by switching to the HA TECH kit. Furthermore, HA TECH’s kit targets conserved regions (3 genes) of the SARS-CoV-2 virus and has shown to be 100 percent accurate for new variants so far. “Our kit has been developed in consideration of the mutating nature of this virus to target three highly conserved SARS-CoV-2 genes, reducing the chance of false negatives,” notes Dr Hani Nur, Managing Director and CSO. The Covid-19 testing kit is also universal and can be used with any 4 channel PCR machine and is compatible with any manual and RNA extraction system.

HA TECH’s Respiratory Combo Kit (NAT-02) is soon to be released, targeting SARS-CoV-2, Influenza A and B, and RSV respiratory virus in one assay.

The symptoms of COVID-19 can be similar to other respiratory diseases and this multiplex test can help healthcare professionals rule out other options in one test.

An example of how HA TECH has helped clients overcome challenges is when one of its new clients wanted an RNA extraction process for sample processing prior to PCR where previously they were following an extraction-free method. The client asked HA TECH to help with a complete solution using our RT-PCR testing kits, Extraction System and Extraction kits. HA TECH provided the client with its HA Tech Extraction System and Kit within a very short time frame and offered free leasing of the extraction machine with extraction kits at a very competitive price. The client was able to increase their testing capability by 200 percent by utilizing the workflow established by the HA Tech Technical team for the complete solution, from sample collection to test results. The whole process of extraction, PCR run, and data analysis took around 1 hour 20 mins to process 96 samples.

HA Tech believes in the quality and simplification of the process of testing. The company develops products with the following key features: Simple, Innovative, Fast, Efficient & Affordable. HA Tech’s Technical and Management team believes in clear and easy communications with end-users directly. Mahmud comments, “We have successfully implemented this all over the world. Most of our clients are outside of Australia and are a phone call away to receive support. We don’t operate like existing big players where end users wait for weeks to months to get a reply or updates. We take our customers’ requirements as our top priority. We are always open to listen to our clients about their needs or requirements.” Besides unique customer support, HA TECH also collaborates with world-class organizations and experts for research & innovation to develop superior products.

All of HA TECH’s products are developed, validated, and manufactured here in Sydney, Australia. The company follows the world’s strictest regulatory guidelines (TGA), which is applicable to all its products. Furthermore, HA TECH is collaborating with reputable virology labs in Asia, Europe and Australia for the clinical evaluation of its products.

HA TECH plans to expand the presence of our product across the world, especially the North and South American Market. The company has started working toward FDA approval for its products. HA TECH also plans to reduce the complex procedures that exist in standard practices. “Our current products have received excellent feedback from clients regarding ease of use. We are committed and will continue conducting cutting edge research and delivering products that make a difference. Within the next 12-24 months’ time we are expecting to launch our complete Respiratory Panels, STI Series, Fever Panels and Gastro Panels,” Mahmud notes.